ClinicalTrials.gg
TerminatedNCT04601584Updated Sep 21, 2026

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

A Phase 1/2 interventional study of Cohort 1, GNR-084 and Cohort 2, GNR-084 in B-precursor Acute Lymphoblastic Leukemia, ALL and GNR-084, sponsored by AO GENERIUM. Terminated at 3 sites in Russia. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Primary conditionPrecursor Cell Lymphoblastic Leukemia-LymphomaRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Why
  1. The study's listed conditions name Precursor Cell Lymphoblastic Leukemia-Lymphoma, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AO GENERIUM · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The sponsor discontinued the development of the drug for reasons other than safety.
Phase
Phase 1/2
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

It is an open-label dose-escalating study in sequential cohorts to assess safety and pharmacokinetics of GNR-084.

Read the detailed description

Acute lymphoblastic leukemias (ALL) are a heterogeneous group of malignant clonal diseases of the blood system originating from precursor cells of hematopoiesis, predominantly of lymphoid differentiation.

More than 7,200 new cases of ALL are diagnosed annually in the European Union (EU), with approximately 40% (approximately 3,000 cases) occurring in adults The main reason for the failure of treatment of acute B-cell lymphoblastic leukemias (B-ALL) is the primary refractoriness to chemical exposure and relapses of the disease, which actually occur in 40-50% of adult patients with ALL. The prognosis in these cases is regarded as extremely unfavorable. Escalation of the chemotherapeutic approach is associated with the development of severe toxic infectious and hemorrhagic complications.

The active substance of the preparation GNR-084 is a bispecific antibody to CD19 / CD3 in the BiMS format (bispecific IgG-like molecules).

02

Conditions studied

  • B-precursor Acute Lymphoblastic Leukemia
  • ALL
  • GNR-084

Keywords

  • Leukemia
  • GNR-084
  • ALL
  • Blood Diseases
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Leukemia, Lymphoid
  • Neoplasms by Histologic Type
  • Neoplasms
  • Lymphoproliferative Disorders
  • Lymphatic Diseases
  • Immunoproliferative Disorders
  • Immune System Diseases
  • Neoplastic Processes
  • Pathologic Processes
  • Antineoplastic Agents
03

In context

Precursor Cell Lymphoblastic Leukemia-Lymphoma Reclassified

2,584 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.

This study's enrollment of 14 is below the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Lead sponsor

AO GENERIUM is the lead sponsor of 31 studies on the registry; 3 are open to participants now.

Compared within Precursor Cell Lymphoblastic Leukemia-Lymphoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed form to participate in the study;
  2. Men and women between aged 18 to 45 inclusive;
  3. Patients with incurable morphologically / immunophenotypically confirmed / relapse of B-cell precursors CD19-positive acute lymphoblastic leukemia from (Ph "-" or Ph "+").
  4. Two or more previous lines of anti-leucosis therapy.
  5. 5-50% of bone marrow blast cells at screening;
  6. Functional status on the scale of the (ECOG) 0-2 points at the screening;
  7. ≥ 60 days;

Exclusion criteria

Exclusion Criteria:

  1. Hematopoietic stem cells transplantation within 12 weeks prior to study inclusion;
  2. Active and widespread chronic graft versus host () reaction (grade II-IV), including taking for the prevention and treatment of GVHD within 2 weeks prior the GNR-084 infusion;
  3. Investigator and / or sponsor has doubts that patient will complete the study due to rapid disease progression;
  4. Chemotherapeutic agent using within 14 days prior the first GNR-084 infusion;

    Exceptions:

    • Emergency leukapheresis;
    • Emergency hydroxyurea using due to hyperleukocytosis for ≤ 7 days;
    • Other supportive care, including antibiotics, at Investigator's discretion
  5. Biochemical blood test:

    • The level of total > 1.5 upper limit of norm;
    • (AST) and Alanine aminotransferase (ALT)> 3 upper limit of norm;
    • (GFR) level ≤30 (СKD-EPI)
  6. Medical history of blinatumomab and other bispecific antibodies using;
  7. Persistent toxicity event of 3rd and 4th severity degrees ( ver 5.0) due to previous treatment;
  8. -positive status and / or detection of any and / or blood markers;
  9. Severe cardiovascular diseases: uncontrolled arterial hypertension, (NYHA) functional class III or IV chronic heart failure, unstable angina pectoris, stroke, myocardial infarction, , coronary artery bypass grafting and coronary revascularization within last 12 months, or signs of pericardial effusion;
  10. Individual sensitivity to:

    • GNR-084 components / ;
    • human or humanized drug antibodies;
  11. Major surgical interventions, accompanied by hospitalization and anesthesia application within 30 days before the patient is included in the study ( is not a significant surgical intervention);
  12. Any other malignant neoplasm presence at the present time or within 5 years prior to inclusion in the study;
  13. Known suspected Central Nervous System (CNS) lesion by any genesis now or in medical history, including, but not limited to: neuroleukemia, epilepsy, ischemic or hemorrhagic stroke, severe traumatic brain injury, dementia, Parkinson's disease, organic brain damage, cerebellar disorders, psychosis;
  14. Extramedullary lesion of any localization;
  15. Other clinical trials participation within 30 days before screening;
  16. Mental, physical and other reasons hindering patient to adequately assess their behavior and correctly comply with the conditions of the research protocol;
  17. Pregnancy and / or lactation;
  18. Male and female patients refusal to use adequate methods of throughout the study;
  19. Drug addiction;
  20. Alcohol addiction.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    GNR-084, dose level 1

    Anti-CD19/CD3 antibody

    Biological: Cohort 1, GNR-084

  • Experimental
    GNR-084, dose level 2

    Anti-CD19/CD3 antibody

    Biological: Cohort 2, GNR-084

  • Experimental
    GNR-084, dose level 3

    Anti-CD19/CD3 antibody

    Biological: Cohort 3, GNR-084

  • Experimental
    GNR-084, dose level 4

    Anti-CD19/CD3 antibody

    Biological: Cohort 4, GNR-084

  • Experimental
    GNR-084, dose level 5

    Anti-CD19/CD3 antibody

    Biological: Cohort 5, GNR-084

  • Experimental
    GNR-084, dose level 6

    Anti-CD19/CD3 antibody

    Biological: Cohort 6, GNR-084

Interventions

  • BiologicalCohort 1, GNR-084

    0.01 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles

    Also known as: Anti-CD19/CD3 antibody

  • BiologicalCohort 2, GNR-084

    0.1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles

    Also known as: Anti-CD19/CD3 antibody

  • BiologicalCohort 3, GNR-084

    1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles

    Also known as: Anti-CD19/CD3 antibody

  • BiologicalCohort 4, GNR-084

    4 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles

    Also known as: Anti-CD19/CD3 antibody

  • BiologicalCohort 5, GNR-084

    10 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles

    Also known as: Anti-CD19/CD3 antibody

  • BiologicalCohort 6, GNR-084

    20 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles

    Also known as: Anti-CD19/CD3 antibody

06

What researchers measure

Primary outcomes

  1. GNR-084 safety and tolerability.

    The GNR-084 safety and tolerability will be assessed based on an analysis of the frequency of adverse events (AEs) over the period of treatment and observation of patients

    Time frame: Week 10

Secondary outcomes

  1. The frequency of specific toxicity events

    Time frame: Week 104

  2. GNR-084 Peak Plasma Concentration (Cmax)

    Time frame: First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.

  3. GNR-084 area under the plasma concentration versus time curve (AUC)

    Time frame: First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.

  4. GNR-84 half-life (T1/2)

    Time frame: First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.

  5. GNR-084 elimination rate constant (Kel)

    Time frame: First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.

  6. GNR-084 mean retention time (MRT)

    Time frame: First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.

  7. GNR-084 overall clearance (Cl)

    Time frame: First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.

  8. GNR-084 kinetic volume of distribution (Vz)

    Time frame: First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.

  9. Peripheral blood B-lymphocyte depletion (CD19, CD20).

    Time frame: First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion

  10. CD45+ peripheral cell count

    Time frame: First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion

  11. Peripheral T-lymphocytes count (CD3, CD4, CD8)

    Time frame: First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion

  12. Peripheral T-memory cells (CD45RA+, CD28+, CCR7+) count

    Time frame: First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion

  13. Peripheral B-cells/T-cells ratio

    Time frame: First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion

  14. Cytokine dynamics

    Time frame: First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion

  15. Immunogenicity

    Time frame: Week 33

  16. Objective response rate (ORR)

    Time frame: After 2 and 5 GNR-084 cycles (each cycle is 28 days)

  17. Complete clinical and hematological remission rate (CR)

    Time frame: After 2 and 5 GNR-084 cycles (each cycle is 28 days)

  18. Frequency of complete remission with incomplete restoration of blood cellularity (CRi)

    Time frame: After 2 and 5 GNR-084 cycles (each cycle is 28 days)

  19. Duration of an objective response (DoR)

    Time frame: Week 104

  20. Relapse-free survival (RFS)

    Time frame: Week 104

  21. Event-free survival (EFS)

    Time frame: Week 104

  22. Overall survival (OS)

    Time frame: Week 104

  23. Minimal residual disease (MRD) (-) rate in CR-patient

    Time frame: After 5 GNR-084 cycles (each cycle is 28 days)

07

Study locations

3 sites
  • Federal State Budget Funded Institution National Medical Research Center of Hematology, Ministry of Health of the Russian Federation (MoH of Russia)
    Moscow, 125167, Russia
  • Almazov National Medical Research Centre
    Saint Petersburg, 191014, Russia
  • Pavlov First Saint Petersburg State Medical University
    Saint Petersburg, 197022, Russia
08

References and documents

Publications

  • Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704. PubMed 35622074 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Dec 2024, 50 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2020
First posted
Oct 26, 2020
StartActual
Oct 15, 2020
Primary completionActual
Dec 18, 2024
CompletionActual
Dec 18, 2024
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04601584
Lead sponsor
AO GENERIUM
Responsible party
Sponsor
First posted
Oct 26, 2020
Start date
Oct 15, 2020
Primary completion
Dec 18, 2024
Completion
Dec 18, 2024
Last update
Sep 21, 2026

Study contacts

Oksana A. Markova, MD
study chair · AO GENERIUM

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion